product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-Src (Ser17) (D7F2Q) Rabbit mAb
catalog :
12432
clonality :
monoclonal
host :
rabbit
conjugate :
nonconjugated
clone name :
D7F2Q
reactivity :
human, mouse, rat
application :
western blot, immunoprecipitation
more info or order :
citations: 2
Published Application/Species/Sample/Dilution | Reference |
---|---|
| Ji H, Li B, Zhang S, He Z, Zhou Y, Ouyang L. Crk-like adapter protein is overexpressed in cervical carcinoma, facilitates proliferation, invasion and chemoresistance, and regulates Src and Akt signaling. Oncol Lett. 2016;12:3811-3817 pubmed
|
|
product information
SKU :
12432S
Product-Name :
Phospho-Src (Ser17) (D7F2Q) Rabbit mAb
Size :
100 ul
Price-(USD) :
274 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Immunoprecipitation
Product-Category :
MAP Kinase Signaling
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
60
Host :
Rabbit
Target :
Src (Ser17) phosphate
Primary-Protein :
Src
Alt-Names :
ASV,Proto-oncogene c-Src,Proto-oncogene tyrosine-protein kinase Src,SRC,SRC1,c-SRC,p60-Src,pp60c-src,protooncogene SRC, Rous sarcoma,tyrosine kinase pp60c-src,tyrosine-protein kinase SRC-1,v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)
more info or order :
company information
Cell Signaling Technology
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.
review
product type
related products
browse more products
questions and comments